• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Up and Coming

Up and Coming

January 4, 2021

This feature highlights changes in clinical trial organizations’ personnel.

3T Biosciences

3T Biosciences has named John Connolly interim CEO of the company. Connolly was most recently chief scientific officer at Tessa Therapeutics.

AB2 Bio

AB2 Bio has appointed Djordje Filipovic as its chief commercial officer. Filipovic most recently served as an executive overseeing the development and commercialization of small molecules and monoclonal antibodies at Novartis.

Aldevron

Aldevron has appointed Matt Johnson vice president of information technologies (IT). Most recently, Johnson was assistant vice president of IT and site operations at Assertio Therapeutics.

Allterum Therapeutics

Allterum Therapeutics has added Philip Breitfeld to its staff as the company’s new chief medical officer. Prior to this appointment, Breitfeld was the chief strategy and innovation officer at Champions Oncology.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals has named Tolga Tanguler its new chief commercial officer. Tanguler most recently was the senior vice president and head of U.S. at Alexion.

Amylyx Pharmaceuticals

Erin Whitney has been appointed head of global clinical operations at Amylyx Pharmaceuticals. Formerly, Whitney was director of clinical development operations at bluebird bio. Amylyx has also hired Shauna Horvath, former brand strategy consultant at Amylyx, as head of global marketing. Keith White has been named Amylyx’s head of global market access. White was most recently vice president of global market access and pricing at Corbus Pharmaceuticals.

Cidara Therapeutics

Christopher Kurtz has been named executive vice president of technical operations at Cidara Therapeutics. Prior to this appointment, Kurtz was the head of commercial API manufacturing at Gilead Sciences.

CorVista Health

Scott Burger has been tapped to serve as CorVista Health’s chief commercial officer and vice president. Formerly, Burger was a director in Johnson & Johnson’s cardiovascular group.

Cyclerion Therapeutics

Cyclerion Therapeutics has promoted Cheryl Gault from senior vice president and head of strategy and corporate development to chief operating officer.

Enara Bio

Erik Rutjens has been hired to serve as Enara Bio’s vice president of cell therapy operations. Rutjens most recently served as head of enabling technologies and process engineering at Novartis.

Equillium

Dolca Thomas has been named executive vice president of R&D and chief medical officer of clinical-stage biotechnology company Equillium. Thomas was most recently chief medical officer of Principia Biopharma.

Evelo Biosciences

Jonathan Zung has been named chief development officer of Evelo Biosciences. Previously, Zung served as the president of sponsor and CRO programs at WCG Clinical.

Karyopharm Therapeutics

Michael Mano, former counsel for business development at Biogen, has been appointed senior vice president and general counsel at Karyopharm Therapeutics.

NodThera

Donald Johns has joined NodThera as the company’s newest chief medical officer. Johns most recently served in the same role at Syntimmune.

Novavax

Novavax has named Rick Crowley as its new chief operating officer. Crowley was previously the executive vice president of technical operations at TerSera Pharmaceuticals.

Royalty Pharma

Jim Reddoch, co-head of research and investments at Royalty Pharma, has been named chief scientific officer. Royalty Pharma has also promoted Marshall Urist from the role of senior vice president to executive vice president and co-head of research and investments. Sandy Balkin, former head of data and strategy at Truist Securities, has joined Royalty Pharma as its newest senior vice president of strategy and analytics.

Sage Therapeutics

Barry Greene, former president of Alnylam, has taken the helm of Sage Therapeutics as its newest CEO.

Saniona

Clinical-stage biopharmaceutical company Saniona has appointed Kyle Haraldsen to the role of chief technical operations officer. Haraldsen was formerly the vice president of technical operations and project management at AMAG Pharmaceuticals.

Swedish Orphan Biovitrum

Duane Barnes, former president of UCB Pharma, has been named head of North America at Swedish Orphan Biovitrum.

Tekscan

Jeff Ames has been appointed president and CEO of Tekscan. Most recently, Ames was vice president and general manager of Kaman Distribution.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing